Articles related to SQUAMOUS CELL CARCINOMA
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
Neoadjuvant cemiplimab was administered to a total of 79 individuals. Upon independent review, a pathological complete response (51 percent; 95% confidence interval [CI], 39 to 62) was noted in 40 patients, and a pathological substantial response (13 percent; 95% CI, 6 to 22) was noted in 10 patients. These outcomes matched the abnormal reactions identified during the investigator’s examination. Fifty-four (54) patients (68%; 95% CI, 57 to 78) had an objective response on imaging, and 69 individuals (87%) experienced adverse events of any grade that happened throughout the course of the study, regardless of whether they were linked to the study treatment. Fourteen (14) participants (18%) experienced adverse events of grade 3 or higher during the research period.
Dermatology October 31st 2022
Cosibelimab Safe, Clinically Active in Patients With mCSCC
In Study CK-301-101, the primary efficacy endpoint was objective response rate (complete + partial response, by independent central review), which was 47% (n = 15) in 32 metastatic cutaneous squamous cell carcinoma (mCSCC) patients evaluable for response, including three complete responses and 12 partial responses. The results from the study were presented at the ESMO Congress.
Dermatology September 28th 2020
FDA Approves Nivolumab for Treatment of Certain Patients With ESCC
Based on the data from the ATTRACTION-3 clinical trial, the FDA approved nivolumab (Opdivo; BMS) for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) who previously received fluoropyrimidine- and platinum-based chemotherapy.
Gastroenterology June 15th 2020